Corinne Jenkins
Stock Analyst at Goldman Sachs
(1.74)
# 3,167
Out of 4,876 analysts
62
Total ratings
44.19%
Success rate
-3.28%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corinne Jenkins
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $59 → $66 | $62.73 | +5.21% | 8 | Dec 5, 2024 | |
| TGTX TG Therapeutics | Maintains: Neutral | $20 → $22 | $36.72 | -40.09% | 8 | Nov 5, 2024 | |
| FULC Fulcrum Therapeutics | Upgrades: Buy | $6 → $15 | $7.10 | +111.27% | 2 | May 14, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $53 → $46 | $21.37 | +115.26% | 5 | May 13, 2024 | |
| ROIV Roivant Sciences | Maintains: Buy | $16 → $18 | $11.39 | +58.03% | 5 | Apr 3, 2024 | |
| GERN Geron | Maintains: Buy | $4 → $5 | $1.49 | +235.57% | 3 | Mar 15, 2024 | |
| ALT Altimmune | Reinstates: Neutral | $13 | $3.50 | +271.43% | 3 | Jan 24, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Sell | $25 → $28 | $31.98 | -12.45% | 7 | Jan 9, 2024 | |
| SWTX SpringWorks Therapeutics | Maintains: Buy | $47 → $52 | $46.98 | +10.69% | 5 | Nov 29, 2023 | |
| BTAI BioXcel Therapeutics | Maintains: Neutral | $192 → $64 | $1.77 | +3,515.82% | 6 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $216 → $184 | $8.43 | +2,082.68% | 2 | Mar 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $21 | $1.47 | +1,328.57% | 2 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $14 | $3.83 | +265.54% | 2 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $8 | $29.64 | -73.01% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $16 | $0.30 | +5,323.73% | 2 | Dec 15, 2021 |
Rhythm Pharmaceuticals
Dec 5, 2024
Maintains: Buy
Price Target: $59 → $66
Current: $62.73
Upside: +5.21%
TG Therapeutics
Nov 5, 2024
Maintains: Neutral
Price Target: $20 → $22
Current: $36.72
Upside: -40.09%
Fulcrum Therapeutics
May 14, 2024
Upgrades: Buy
Price Target: $6 → $15
Current: $7.10
Upside: +111.27%
IDEAYA Biosciences
May 13, 2024
Maintains: Buy
Price Target: $53 → $46
Current: $21.37
Upside: +115.26%
Roivant Sciences
Apr 3, 2024
Maintains: Buy
Price Target: $16 → $18
Current: $11.39
Upside: +58.03%
Geron
Mar 15, 2024
Maintains: Buy
Price Target: $4 → $5
Current: $1.49
Upside: +235.57%
Altimmune
Jan 24, 2024
Reinstates: Neutral
Price Target: $13
Current: $3.50
Upside: +271.43%
Harmony Biosciences Holdings
Jan 9, 2024
Maintains: Sell
Price Target: $25 → $28
Current: $31.98
Upside: -12.45%
SpringWorks Therapeutics
Nov 29, 2023
Maintains: Buy
Price Target: $47 → $52
Current: $46.98
Upside: +10.69%
BioXcel Therapeutics
Aug 15, 2023
Maintains: Neutral
Price Target: $192 → $64
Current: $1.77
Upside: +3,515.82%
Mar 15, 2023
Maintains: Buy
Price Target: $216 → $184
Current: $8.43
Upside: +2,082.68%
Mar 7, 2023
Maintains: Buy
Price Target: $25 → $21
Current: $1.47
Upside: +1,328.57%
Dec 20, 2022
Maintains: Buy
Price Target: $9 → $14
Current: $3.83
Upside: +265.54%
May 24, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $29.64
Upside: -73.01%
Dec 15, 2021
Initiates: Neutral
Price Target: $16
Current: $0.30
Upside: +5,323.73%